Saturday, June 1, 2019, Chicago, Illinois, 7:00 PM – 9:30 PM

Addressing Current Questions and Controversies in the Management of Gastrointestinal Cancers

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Professor Dirk Arnold, MD, PhD
Asklepios Tumorzentrum Hamburg
AK Altona
Hamburg, Germany

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of
Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Vice-Chair and Section Lead
Division of Medical Oncology
Medical Director, Cancer Clinical Research Office
Senior Associate Consultant
Mayo Clinic
Phoenix, Arizona

Joseph Chao, MD
Assistant Clinical Professor
Department of Medical Oncology and
Therapeutics Research
Gastrointestinal Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California

Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Medical Director of Clinical Investigations Support Office
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California

Richard S Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Yelena Y Janjigian, MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Scott Kopetz, MD, PhD
Associate Professor, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Eileen M O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary/
Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director

David M Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Eisai Inc, Exelixis Inc, Genentech, Ipsen Biopharmaceuticals Inc, Lilly, Merck and Taiho Oncology Inc.
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting

Meeting Agenda and Format

Prior to the event, RTP will work with a group of 5 community-based medical oncologists to collect challenging cases from their practices in addition to any relevant questions these individuals have related to the care of their patients. To begin each meeting module, Dr Love will present one or more of these cases and the related questions and ask the faculty to provide their perspectives. Afterward, the faculty will review available data sets and provide perspectives on their clinical implications as part of a moderated discussion.

MODULE 1: Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry and Dr Finn

  • Efficacy and safety outcomes from the Phase III REFLECT trial comparing lenvatinib to sorafenib as first-line therapy for unresectable HCC; recent FDA approval of lenvatinib and patient selection for its use in routine practice
  • Available data with and sequence and selection of approved agents (nivolumab, regorafenib, cabozantinib, pembrolizumab) for patients whose disease has progressed on first-line therapy
  • Key findings from the Phase III REACH-2 study of ramucirumab for patients with progressive HCC and elevated alpha-fetoprotein levels; future development plans
  • Biologic rationale for and early trial data with atezolizumab/bevacizumab as first-line therapy for advanced HCC; FDA breakthrough therapy designation and ongoing Phase III evaluation
  • Biologic rationale for, early safety and efficacy with and ongoing evaluation of combined anti-PD-1/PD-L1 and anti-CTLA-4 antibodies in HCC (eg, nivolumab/ipilimumab, durvalumab/tremelimumab)
  • Active Phase III trials attempting to improve outcomes over standard biologic therapy for patients with newly diagnosed, advanced HCC (eg, CheckMate 459, LEAP-002, COSMIC-312)

MODULE 2: Pancreatic Adenocarcinoma (PAD) — Dr Bekaii-Saab and Dr O’Reilly

  • Key outcomes from and clinical implications of the randomized Phase III Unicancer GI PRODIGE 24/CCTG PA.6 trial comparing adjuvant mFOLFIRINOX to gemcitabine for resected PAD
  • Preliminary results from the Phase III APACT trial evaluating nanoparticle albumin-bound (nab) paclitaxel/gemcitabine versus gemcitabine alone in the adjuvant setting
  • Use of contemporary chemotherapy regimens (mFOLFIRINOX, nab paclitaxel/gemcitabine) with or without radiation therapy as neoadjuvant treatment for resectable or borderline-resectable PAD
  • Published research experience with, patient selection for and practical integration of nal-IRI (nanoliposomal irinotecan) in relapsed metastatic PAD
  • Design, eligibility criteria and achievement of the primary progression-free survival endpoint in the Phase III POLO trial evaluating olaparib as maintenance therapy for patients with metastatic PAD with a germline BRCA mutation after first-line chemotherapy; diagnostic and clinical implications
  • Mechanism of action, early activity and safety data and ongoing Phase III evaluation of other novel agents (eg, napabucasin, PEGPH20)

MODULE 3: Gastroesophageal Cancers — Dr Chao and Dr Janjigian

  • Integration of ramucirumab into current clinical algorithms for metastatic gastric/gastroesophageal junction (GEJ) cancer
  • Research supporting the FDA approval of pembrolizumab for recurrent or advanced gastric/GEJ adenocarcinoma with a PD-L1 combined positive score (CPS) ≥1 after 2 or more lines of chemotherapy and, if appropriate, HER2-targeted therapy; clinical and research implications of the Phase III KEYNOTE-061 and KEYNOTE-062 trials
  • Early experience and ongoing research combining immune checkpoint inhibitors with chemotherapy, targeted therapy or other immunotherapeutic agents
  • Primary and secondary endpoints achieved in the Phase III TAGS study of TAS-102 for heavily pretreated metastatic gastric cancer; FDA approval and patient selection in routine practice
  • Results from the Phase III KEYNOTE-181 trial evaluating second-line pembrolizumab versus chemotherapy for locally advanced or metastatic squamous cell carcinoma and adenocarcinoma of the esophagus; potential role of pembrolizumab for progressive, PD-L1-positive advanced esophageal cancer

MODULE 4: Colorectal Cancer (CRC) — Prof Arnold and Dr Kopetz

  • Available research data exploring the correlation between tumor location and long-term outcomes in metastatic CRC (mCRC); emerging data linking tumor sidedness to response to specific therapeutic interventions
  • Rational incorporation of EGFR antibodies, regorafenib and TAS-102 into current treatment algorithms
  • Published research information with the use of novel combination approaches for patients with advanced disease harboring a BRAF V600E tumor mutation (eg, irinotecan/vemurafenib/cetuximab, encorafenib/binimetinib/cetuximab); NCCN guideline inclusion and current clinical role, if any
  • Research supporting the FDA approvals of pembrolizumab, nivolumab and nivolumab/ipilimumab for microsatellite instability (MSI)-high/mismatch repair-deficient mCRC
  • Biologic rationale for, available research evidence with and ongoing evaluation of other immune checkpoint inhibitors alone or in combination with other systemic therapies for patients with MSI-high and microsatellite-stable mCRC

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal (GI) cancers.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer, considering the patient’s biomarker profile, tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastroesophageal cancers.
  • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
  • Recall available clinical trial data with approved and investigational systemic interventions, and where appropriate, apply this information to the current clinical care of patients with locally advanced or metastatic hepatocellular carcinoma.
  • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
  • Counsel appropriately selected patients with GI cancers about participation in ongoing clinical trials evaluating other novel therapeutic agents and strategies.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Eisai Inc, Exelixis Inc, Genentech, Ipsen Biopharmaceuticals Inc, Lilly, Merck and Taiho Oncology Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.


Thank you for your interest in our educational program. At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM on Saturday, June 1st. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients, and meal service will be offered based on availability. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.